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SCIENTIFIC JUDGMENT AND TOXIC
TORTS—A PRIMER IN TOXICOLOGY FOR
JUDGES AND LAWYERS
David L. Eaton, Ph.D., DABT, FATS*
I.

GENES, ENVIRONMENT AND DISEASE

Remarkable progress has been made in the past decade in
understanding the molecular basis of many chronic diseases such
as cancer, degenerative neurological diseases (Alzheimer’s,
Parkinson’s), heart disease, and asthma. Although the molecular
basis for such diseases has become more apparent, the exact
“cause” is seldom identified for a disease in general, and especially
for a disease in an individual. It is now recognized, however, that
most such chronic diseases result from a complex interplay
between our genes and our environment. While our parents
predetermine our genes, our environment is somewhat
controllable, and thus identifying “environmental risk factors” for
chronic diseases holds great promise for disease prevention. It
should be noted that “environment” in this context represents
virtually everything in the world around us that is not “in our
genes.” Thus environmental factors include lifestyle choices such
as smoking, drug use and alcohol consumption, exposure to
infectious agents (viruses, bacteria), as well as diet and nutrition,
environmental pollution (air, water), and even behavioral and
social factors such as exercise, reproductive choices, sexual
activity, etc.
There is currently great scientific effort committed to
* Professor of Environmental and Occupational Health Sciences; Associate
Dean for Research School of Public Health and Community Medicine at the
University of Washington.
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identifying specific genetic characteristics (so-called “genetic
polymorphisms”) that make one individual more susceptible to
something in the environment than another.1 This area of research
is sometimes referred to as “ecogenetics,” or the study of “geneenvironment interactions.”2 There are many classic examples of
genetic characteristics that make an individual sensitive to
something in his environment. For example, the rare genetic
disease, phenylketonuria (PKU), makes individuals with this
genetic trait very sensitive to a normal component of our diet—
phenylalanine. Phenylalanine is a normal building block of
proteins, and in most people is an important nutrient in the diet.
For a small part of the population with a mutation in the PKU
gene, however, regular “doses” of phenylalanine found in the
normal diet can lead to serious mental retardation if infants are
exposed to phenylalanine. Because of this, genetic testing for PKU
is mandatory in most states in the United States and is part of
normal newborn screening. Those rare individuals who test
positive for PKU can lead normal lives by following special diets
and avoiding foods rich in phenylalanine.
Another common example of a “gene-environment” interaction
occurs in many people of Asian descent who carry a genetic
variant of a gene involved in alcohol metabolism. Normally,
alcohol is fairly rapidly detoxified in the liver. But individuals with
a variant form of the gene for an enzyme called “aldehyde
dehydrogenase” (ALDH2) are less able to eliminate a toxic byproduct of alcohol metabolism, acetaldehyde. If a person with the
variant ALDH2 gene consumes even modest amounts of alcohol,
toxic amounts of acetaldehyde can accumulate in the blood,
causing a very uncomfortable reaction (“flushing” of the skin from
vasodilatation, nausea, headache). Not surprisingly, alcoholism and
alcohol-related diseases such as cirrhosis of the liver occur very
1

See Samir N. Kelada, David L. Eaton, Sophia S. Wang, Nathaniel R.
Rothman & Mhuin J. Khoury, The Role of Genetic Polymorphisms in
Environmental Health, 111 ENVTL. HEALTH PERSP. 1055-64 (2003).
2
Gilbert S. Omenn, Public Health Genetics: An Emerging Interdisciplinary
Field for the Post-Genomic Era, 21 ANN. REV. OF PUB. HEALTH 1, 1-13 (2000);
Daniel W. Nebert & Michael J. Carvan, III, Ecogenetics: From Ecology to
Health, 13 TOXICOLOGY AND INDUSTRIAL HEALTH 163, 163-92 (1997).
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infrequently in people with this genetic trait.
There is currently a great deal of interest in identifying
common genetic traits that might combine with factors in our
environment to cause disease. It is hoped that, one day, physicians
will be able to characterize, or “genotype,” the entire genetic code
of a person, and based on the results (kept on a personal microchip
medical card), identify whether the patient is at increased risk for
certain diseases and potentially identify specific dietary,
workplace, or other environmental factors that should be avoided
to lower risk. While we are still a decade or more away from
having scientifically validated tests for “environmental
susceptibility” to most environmental/occupational hazards, similar
approaches for identifying how individuals respond to therapeutic
drugs is just around the corner (the field of “Pharmacogenomics”).
Indeed, there are now several relatively widespread genetic tests
that can identify in advance patients who are likely to have adverse
reactions to otherwise “normal” therapeutic doses of specific
drugs.3 The concept of “designer drugs” is becoming a reality, but
so far in a limited way. For example, there is a common genetic
variant in a gene called “N-acetyl transferase.” This gene is
involved in the detoxification of a variety of therapeutic drugs, and
people with the “slow” genetic variant exhibit increased toxicity
(but also enhanced therapeutic effects at lower doses) to a variety
of common drugs. Knowing this predisposition in advance allows
physicians to prescribe the proper dose.
How will such genetic information be used in the courtroom?
In the realm of genetic testing for drug sensitivity, there will be
medical malpractice claims filed against physicians who fail to
order genetic tests before prescribing certain drugs, once such
procedures become the standard of care.4 Drug companies will
3

Rafael Valdes Jr., Mark W. Linder & Saeed A. Jortani, What Is Next in
Pharmacogenomics?
Translating
It
to
Clinical
Practice,
4
PHARMACOGENOMICS 499, 499-505 (2003).
4
Jan van Aken, Mechteld Schmedders, Gunter Feuerstein & Regine
Kollek, Prospects and Limits of Pharmacogenetics: The Thiopurine Methyl
Transferase (TPMT) Experience, 3 AM. J. OF PHARMACOGENOMICS 149, 149-55
(2003); Mark A. Rothstein & Sharona Hoffman, Genetic Testing, Genetic
Medicine, and Managed Care, 34 WAKE FOREST L. REV. 849 (1999).
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attempt to increase drug safety and limit liability by identifying in
advance drugs that may elicit adverse responses in small segments
of the population because of genetic sensitivity. In the
environmental and occupational arena, employers might use
genetic tests as a way of identifying and removing “sensitive”
individuals from certain workplace exposures.5 While such
practice might conceivably lower the occurrence of chemicalinduced occupational diseases, it is obviously also a means of
employment discrimination. It is also likely that plaintiff and
defense attorneys will utilize genetic susceptibility as an argument
for, or against, causation in toxic tort cases. Currently, however,
the scientific data supporting the use of genetic susceptibility
information in toxic tort litigation is extremely limited.6 In the vast
majority of circumstances, specific and measurable genetic
“susceptibility markers” often do little more than shift a person
“up” or “down” the dose-response curve. Such differences tend to
be modest (less than a two-fold difference in susceptibility), and
the impact of the genetic trait is often lost in the “noisy
background” of poor exposure assessment.7 That is, if one can only
“guess” the dose, duration, and frequency of exposure to a specific
chemical within a factor of 5 or 10 (not uncommon in toxic tort
cases), a genetic factor that theoretically doubles or halves the risk
from a given dose will not be particularly informative against the
high level of uncertainty of the actual “exposure.” Thus, although
genetic information will increasingly find its way into toxic tort
5

Robert J. McCunney, Genetic Testing: Ethical Implications in the
Workplace, 17 OCCUPATIONAL MED. 665, 665-72 (2002); Steve M. Bartell,
Raphael A. Ponce, Tim K. Takaro, Richard O. Zerbe, Gilbert S. Omenn &
Elaine M. Faustman, Risk Estimation and Value-of Information Analysis for
Three Proposed Genetic Screening Programs for Chronic Beryllium Disease
Prevention, 20 RISK ANALYSIS 87, 87-99 (2000).
6
Gary E. Marchant, Toxicogenomics and Toxic Torts, 20 TRENDS IN
BIOTECHNOLOGY 329, 329-32 (2002).
7
Werner K. Lutz, Differences in Individual Susceptibility to Toxic Effects
of Chemicals Determine the Dose-Response Relationship and Consequences of
Setting Exposure Standards, 126 TOXICOLOGY LETTER 155, 155-58 (2002);
Marilyn J. Aardema & James T. MacGregor, Toxicology and Genetic
Toxicology in the New Era of “Toxicogenomics”: Impact of “-Omics”
Technologis, 499 MUTATATION RES. 13, 13-25 (2002).
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litigation, the fundamental concepts of toxicology and
epidemiology continue to serve as the foundation for establishing
causation in toxic tort claims.8 The following information is
provided as a “primer” in basic toxicology, as it relates to toxic tort
litigation. For a more detailed discussion of considerations of how
the science of toxicology and epidemiology should be used in the
courtroom, the reader is referred to the Federal Judicial Center’s
Reference Manual on Scientific Evidence.9 This publication
includes chapters devoted to toxicology and epidemiology, as well
as medical testimony and use of DNA in the courtroom.
II. BASIC TOXICOLOGY RELEVANT TO TOXIC TORT LITIGATION
Toxic substances may take many forms, including both humanmade (synthetic) and natural chemicals. Although the adverse
effects of physical agents such as ionizing radiation fall under the
broad rubric of toxicology, this discussion will focus on chemical
agents. There are many “sub-disciplines” within the field of
toxicology, and a variety of approaches and techniques are used to
evaluate the toxicological characteristics of chemicals. A detailed
review of the basic principles of toxicology is beyond the scope of
this article.10 The following brief review highlights some of the
key principles of toxicology that must be considered in any attempt
to establish whether a chemical exposure was causally related to a
specific adverse effect or disease in an individual.

8

Mark Parascandola & Douglas L. Weed, Causation in Epidemiology, 55
J. EPIDEMIOLOGY COMMUNITY HEALTH 905, 905-12 (2001); see Marchant,
supra note 6.
9
FEDERAL JUDICIAL CENTER, REFERENCE MANUAL ON SCIENTIFIC
EVIDENCE (2d ed. 2000).
10
A number of fundamental textbooks are available that review the
principles of toxicology in depth. See J. MARK ELWOOD, CAUSAL
RELATIONSHIPS IN MEDICINE (1988); ALFRED S. EVANS, CAUSATION AND
DISEASE (1993); KENNETH J. ROTHMAN, CAUSAL INFERENCE (1988); MERVYN
W. SUSSER, CAUSAL THINKING IN THE HEALTH SCIENCES (1973).
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A. Types of Adverse Effects Produced by Chemicals

Virtually all substances are capable of inducing some form of
toxic effect, and the type and nature of effects will vary depending
on the
• dose (amount of substance that finds its way into the body)
• route (i.e., oral, inhalation, skin; injection)
• duration (days, weeks, months, years) and
• frequency (how many times per day, week, month, year)
of exposure.
A given chemical does not cause every possible effect, and the
ability of a chemical to cause a particular effect depends upon a
variety of factors, as discussed below. Typically, a specific
chemical elicits a characteristic pattern of toxic (adverse) effects,
although the appearance of specific effects will depend on the dose
and other characteristics of exposure. Sometimes chemicals of a
common type cause a generalized adverse response. For example,
nearly all organic solvents derived from petroleum products
(including mixtures such as gasoline or kerosene, or individual
solvents such as benzene, hexane, or toluene) share some (but not
all) symptoms in common: “defatting” of the skin following
dermal exposure, and central nervous system depression
(inebriation, loss of consciousness) following relatively high levels
of inhalation exposure. However, even though different chemicals
of the same general type (e.g., solvents) may have some common
effects, they may also differ dramatically in other effects. For
example, the industrial solvents benzene and toluene are very
similar chemically, and share many common toxic effects noted
above for solvents, but benzene is toxic to the bone marrow and
can increase the risk of leukemia in workers, whereas these serious
toxic effects have not been found for toluene. Thus, some
chemicals act in very specific ways at the cellular level, and their
effects may be largely limited to a characteristic type of response.
As an example, the widely-used class of insecticides known as
“organophosphates” inhibit a specific enzyme in the nervous
system (acetylcholinesterase), and most of the signs and symptoms
of toxicity can be attributed to this one mode of action. However,
even small differences in chemical structure can sometimes make
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very large differences in the type of toxic response that is
produced. This is especially true for chemicals that cause birth
defects (teratogens) or chemicals that increase the risk of cancer
(carcinogens).
B. Concepts of Dose and Exposure
“Dose” refers to the amount of chemical that enters the body.
The units of dose are typically expressed as an amount of
substance per kg of body weight (mg/kg bw). Thus, if a 132 lb
woman (60 kg) absorbed 60 milligrams of a chemical in a glass of
contaminated water, she would have a dose of 1 mg/kg bw. Dose is
the single most important factor to consider in evaluating whether
an alleged exposure caused a specific adverse effect. Indeed, the
basic dictum of toxicology was stated by the Sixteenth Century
Physician/Philosopher, Paracelsus, considered the “father of
toxicology”: “All substances are poisonous—there is none which is
not; the dose differentiates a poison from a remedy.”11
1.

Relationship between “Exposure Concentration” and “Dose”

Dose and “exposure” in terms of media (e.g., air, water, soil)
concentration are related, but not identical, terms. Exposure may
be referred to as the presence of a chemical in a medium (e.g., air,
water, food) that allows for direct contact with potential sites of
absorption (e.g., gastrointestinal tract, lungs, skin). The units of
such exposure are usually expressed as concentrations—e.g.,
milligrams of chemical per liter of water (mg/L), milligrams of
chemical per cubic meter of air (mg/m3), milligrams of chemical
per kilogram of food (mg/kg). Frequently, such concentrations are
expressed as “parts per million” (ppm) or “parts per billion” (ppb).
For chemicals dissolved in water, 1 part per million is the same as
1 milligram of chemical dissolved in 1 liter of water. One part per
billion (1 ppb) is a thousand times less—1 milligram dissolved in a
thousand liters of water, or 1 microgram of chemical dissolved in 1
11

CASARETT AND DOULL’S TOXICOLOGY: THE BASIC SCIENCE OF POISONS
Chs. 1, 4 (Curtis D. Klaassen ed., McGraw Hill 6th ed. 2001) (emphasis added).
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liter of water. A part per trillion (ppt), is 1,000 times less than a
part per billion. To provide some perspective on these units,
consider the following:
• 1 ppm=1 penny in $10,000, or 1 inch in the distance of 15.8
miles
• 1 ppb=1 penny in $10 million, or 1 inch in 15,800 miles
• 1 ppt=1 nickel of Bill Gates net worth (assuming $50
billion), or 6 inches in the distance between the earth and
the sun.
Analytical tools developed in the past several decades make it
possible to measure substances in water, food, soil or air at the ppt
and even parts per quadrillion (ppqd; 1,000 times less than a ppt).
It is evident from these simple analogies that, when discussing
exposure to chemicals in drinking water, air, or soil, it is critically
important that the relationship between exposure, as expressed as a
concentration of a pollutant in a medium (measured in ppm, ppb,
ppt or even ppqd) and the actual dose to a person not be lost. The
science of toxicology can help understand whether the dose of a
substance achieved following a particular exposure has any
relationship to toxicity or disease.
2.

Frequency and Duration of Exposure

Frequency and duration of exposure are important elements of
“dose.” Effects caused by chemicals may differ depending on
whether exposure was short-term (e.g., acute, single dose or a few
days) or long-term (chronic, repeated over years). The dose of a
chemical required to produce health effects also differs with
frequency and duration of exposure. When exposure occurs
repeatedly over weeks, months, or years, the dose is usually
expressed as a dose rate, with units of mg of chemical per kg of
body weight per day. The dose necessary to produce deleterious
effects with short-term exposure is higher than the dose that
produces toxic effects when repeated over a long time period. The
body can usually tolerate or recover from high doses with brief
short-term exposure as compared to long-term repeated exposure.
For example, one night of moderate drinking may give you no
more than a headache the next day, but heavy drinking frequently
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for years could lead to liver cirrhosis and possibly liver cancer.
However, it is also possible that repeated, low dose exposures—
even for many years—will have no consequence at all, since the
body is often able to completely detoxify low doses before they do
any damage. This concept of “thresholds” will be discussed in
more detail later.
Most chemicals that have been identified to have “cancercausing” potential (carcinogens) do so only following long-term,
repeated exposure for many years. Single exposures or even
repeated exposures for relatively short periods of time (e.g., weeks
or months) generally have little effect on the risk of cancer, unless
the exposure was remarkably high and associated with other toxic
effects. Relatively infrequent exposure may also have negligible
health consequences even if continued over time because of
recovery between doses.
3.

Pathways and Routes of Exposure

“Pathways” are the means by which an environmental chemical
may reach an “exposed” person. Chemicals can enter the body by
four fundamental “routes”: (1) via oral exposure (e.g., ingestion of
the toxic substance directly, or in food or drinking water), (2) via
inhalation (e.g., breathing air or inhaling dust contaminated with
the toxic substance), (3) via direct contact with the skin (e.g.,
spilling of a pesticide mixture on the skin), or (4) by direct
injection into the body (e.g., introduction of a drug by intravenous
injection). The “bioavailability”—or ability of the chemical to be
taken into the blood stream—differs by route of entry. Most drugs
and toxic chemicals will be well absorbed from the gut when
ingested in a soluble form versus in other media such as soil. Many
chemicals, however, are only slightly absorbed, if at all, if applied
to the skin. However, fat-soluble chemicals in high concentration
may be well absorbed across the skin, and this can lead to an
important pathway of exposure for those using concentrated
solutions in the workplace. The extent of inhalation absorption of
chemical vapor will depend on a variety of factors, including the
relative solubility of the chemical in blood versus air, the rate of
breathing, and even whether one breathes through the nose or
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mouth.
4.

Site of Action in the Body

Ultimately, what matters is the actual concentration of a toxic
substance at the “site of action” in the body. The concentration of a
chemical in any given organ/tissue in the body is determined by
complex interactions between the rates of exposure, and rates of
absorption, distribution, metabolism, and excretion. Because
chemicals differ in their solubility in body fluids/tissues, in how
they are metabolized, and in what cellular processes are altered,
toxic effects of a chemical may be limited to specific tissues or
organs, referred to as its “target tissue.” For example, lead and
mercury typically produce toxic effects associated with the brain
and kidneys, whereas certain chlorinated solvents such as
chloroform and carbon tetrachloride affect predominantly the liver
(although in high doses they also affect the brain).
Many factors determine whether a chemical will be toxic to a
particular organ. Some organs metabolize (biotransform)
chemicals to toxic intermediates, leading to toxicity in that organ.
In such instances, the relative ability of an organ or tissue to
metabolize the chemical may determine whether the toxic effect is
seen in that tissue. Certain tissues may also accumulate a chemical
from the bloodstream at higher rates than other tissues, leading to
toxicity in just that tissue. This is particularly true for tissue with a
function (e.g., liver), but not necessarily for storage tissue, i.e., fat,
which accumulates fat-soluble chemicals such as DDT, but is not
directly injured. Metabolic pathways and the amount and type of
toxic by-products produced or accumulated may also differ
depending on the amount of chemical in the blood stream (which,
of course, is directly related to dose). For example, metabolic
pathways at low doses that result in chemical detoxification may
be overwhelmed at high doses leading to accumulation of toxic
intermediates or production of greater amounts of toxic byproducts by alternative pathways.
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Dose-response Relationship

As noted above, the relationship between dose and effect
(dose-response relationship) is the hallmark of basic toxicology.
The “dose-response” in a given individual describes the
relationship between the magnitude or severity of the effect(s) and
the dose. In many instances, especially for acute toxicity, the slope
of the dose-response curve is quite steep. That is, once a sufficient
dose has been achieved to induce a toxic response, further
increases in the dose may produce large increases in the response.
In the individual, the nature of the response may change with
increasing dose. For example, ingestion of one or two glasses of
wine will result in an apparent “stimulatory” effect on the nervous
system, often expressed as slight changes in personality or
character. Further consumption of alcohol will lead to loss of
coordination and reaction time, slurred speech, etc. Continued
consumption of alcohol beyond this level of intoxication may
result in loss of consciousness and even death.
Although individuals within a population may respond
differently to the same dose of chemical, the reaction of the
population as a whole nevertheless follows a “dose-response
relationship” such that the number of people in a population that
respond to a chemical exposure increases with dose. Inherent in
this concept is that, for the vast majority of chemicals and types of
responses, there are doses below which no individual will respond
(e.g., a “threshold”) and doses above which nearly everyone
responds. For example, no one would exhibit any detectable
adverse effect of a few drops of wine or beer (e.g., the dose is
below the threshold), yet most everyone in a population would
show signs of intoxication after ingestion of an entire bottle of
wine (over a relatively short period of time). In between these two
extremes, there are clearly differences in the level of intoxication
between individuals consuming one, two, three, or four glasses of
wine. In a similar fashion, there is inherent human variability in
response to chronic exposures to chemicals. Dose-response
relationships in populations also exist for both acute and chronic
exposures to toxic substances.
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6.

Concept of “Thresholds”

For most types of dose-response relationships following
chronic (repeated) exposure, thresholds exist, such that there is
some dose below which even repeated, long term exposure would
not cause an effect in any individual. Most toxicological responses,
including neurological, reproductive, and developmental effects,
exhibit thresholds (e.g., there is a dose below which the probability
of an individual responding is essentially zero). One key objective
in toxicology is to identify doses for a population below which no
one will respond. However, in the case of chemical carcinogens,
particularly those that increase risk of cancer by causing direct
damage to DNA in cells, many regulatory agencies assume that
there are no “thresholds,” and that risk is proportionate to dose at
all levels of exposure—e.g., as the dose of carcinogen increases,
the probability of developing cancer increases in a proportionate,
“linear” fashion.
Nonetheless, many scientific and practical reasons indicate
that, at very low doses, the significance of such risks, if real,
become trivial and are lost in the background of other daily risks.
For example, it is well known that cigarette smoking is strongly
associated with increased risk for lung and bladder cancer (and
other types), and that the probability of developing such smokingrelated cancers is related to both the amount (cigarettes per day)
and the frequency (years of smoking) of smoking over a lifetime.12 It is also recognized that the carcinogenic properties of
cigarette smoke are strongly related to the ability of components of
cigarette smoke to damage DNA (cause mutations), and thus it
might be assumed that the dose-response relationship for smoking
would be a “non-threshold” (linear at low doses) response.13
However, while a linear, non-threshold response to cigarette smoke
may be hypothesized on theoretical grounds, from a practical

12

See OFFICE OF THE SURGEON GENERAL, U.S. PUB. HEALTH SERV., DHHS
PUB. NO. (CDC) 90-8416, THE HEALTH BENEFITS OF SMOKING CESSATION: A
REPORT OF THE SURGEON GENERAL (1990).
13
Ralph Zito, Low Doses and Thresholds in Genotoxicity: from Theories to
Experiments, 20 J. EXPERIMENTAL CLINICAL CANCER RES. 315, 315-25 (2001).
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perspective one’s level of increased risk from smoking one
cigarette over a lifetime, or even one cigarette a month for a
lifetime, is not likely to be distinguishable from “background” risk
for cancer from all other causes, known and unknown.
Not all chemical carcinogens increase cancer risk by causing
mutation. For such “non-genotoxic” carcinogens, it is generally
thought that the dose-response relationship follows a typical
threshold-type response. Thus, it is often important to distinguish
between “genotoxic” (particularly those that act directly on DNA
to cause mutations) and “non-genotoxic” carcinogens for
regulatory and risk assessment purposes. Practical thresholds may
also exist for “genotoxic” carcinogens that damage DNA by
indirect mechanisms (e.g., production of sufficient “reactive
oxygen species” to cause oxidative damage, or sufficient inhibition
of DNA repair mechanisms), because a sufficient amount of the
chemical is needed before enough damage to the DNA occurs to
lead to cancerous cells.
C. Chemical Exposures and Chronic Diseases
Traditional toxicology tests in laboratory animals are designed
to identify toxic responses following various periods of exposure.14
Acute toxicity studies examine the toxic effects after single, high
doses and are useful to understand the specific organ systems
affected by the chemical, as well as the general “potency” of its
effect (e.g., does it require microgram, milligram, or gram
quantities to produce evidence of toxicity?). Additional “subchronic” (usually ninety days of daily exposure) and “chronic”
(usually lifetime, or two years of continuous daily exposure)
studies are often done to further examine whether the chemical is
capable of causing other types of toxic effects following repeated
exposures. Such studies may demonstrate that repeated exposure to
a chemical could cause liver or kidney or brain damage, for
example. Special “3-generation” studies may be done in animals to
determine if the chemical can cause reproductive effects and/or
14

CASARETT AND DOULL’S TOXICOLOGY: THE BASIC SCIENCE OF POISONS,
supra note 11, at chs. 2, 11-34.
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birth defects. Today, new chemicals entering commerce, such as a
new pesticide, may be subjected to specialized tests to determine if
it can cause neurological effects on learning and behavior, or cause
toxicity to the immune system. Each of these toxicological endpoints can be the subject of toxic tort litigation. However,
regardless of the end-point, the basic concept of “dose-response”
remains essential in evaluating a causal connection between an
alleged exposure and a particular disease. As noted above, for noncancer end points, it is generally accepted that “thresholds” exist,
and that doses below the threshold represent no risk. However,
determining the “true” threshold for humans is difficult, if not
impossible, and requires consideration of human variability. Thus,
regulatory agencies often determine “safe” levels of exposure for
non-cancer endpoints by dividing the highest dose that does not
cause any evidence of toxicity upon repeated exposure to a group
of laboratory animals (the so-called “No Observable Adverse
Effect Level,” or NOAEL) by some “uncertainty” factor.15 Usually
the factor is 100 or 1000, although the choice of what uncertainty
factor to use is dictated by the nature of the toxic response, the
quality and quantity of the experimental animal data, and the level
of understanding of the mechanism of action of the toxic
substance.
Determining the causal relationship between a chemical
exposure and a particular chronic disease requires careful
consideration of a variety of factors, some of which may be unique
to the particular end point in question. For example, establishing an
association between a particular drug or chemical and a birth
defect requires careful consideration of the exact timing of
exposure during pregnancy. Thalidomide, responsible for
development of thousands of limb malformation in Europe many
decades ago, requires that exposure occur during a very specific
period—as short as a few days—early in pregnancy.16 Exposure to
the drug after the critical period during embryonic development

15

Id. at ch. 4.
Joseph M. Lary, Katherine L. Daniel, J. David Erickson, Helen E.
Roberts & Cynthia A. Moore, The Return of Thalidomide: Can Birth Defects be
Prevented?, 21 DRUG SAFETY 161, 161-69 (1999).
16
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when the limb buds are forming will not produce that particular
birth defect, regardless of dose. Likewise, because the drug is
relatively rapidly eliminated from the body, exposure very early in
pregnancy—but that was stopped several days prior to the period
of limb bud development—also would not produce the birth defect.
Although there is great interest in understanding how
environmental factors might contribute to chronic neurological
diseases such as Alzheimer’s and Parkinson’s disease, there are
relatively few examples where environmental exposures have been
shown to contribute to these diseases. Perhaps the most notable
example is that of a batch of synthetic heroin that was
contaminated with a substance known as MPTP, and subsequently
sold on the streets of San Francisco. Numerous young men (under
the age of 30) presented with “rapid onset” symptoms essentially
identical to Parkinson’s disease. On detailed investigation, it was
learned that they had all used a synthetic heroin substance shown
later to have contained MPTP.17 This substance is selectively toxic
to certain nerve cells in the brain. These same cells, called
“dopaminergic neurons,” are lost progressively with age in all
people, resulting in Parkinson’s disease in some (those with a
somewhat accelerated loss of cells). Thus, the street drug was able
to do in weeks what normally takes a lifetime of “normal” aging.
There is now great interest to find other environmental factors that
might contribute to the enhanced rate of loss of dopaminergic
neurons that seems to be the hallmark of Parkinson’s disease. One
environmental chemical, an herbicide called “paraquat,” has a
strong structural similarity to the active metabolite of MPTP, and
thus there has been substantial toxicological and epidemiological
inquiry into whether environmental or occupational exposure to
paraquat might contribute to Parkinson’s disease. At this point in
time, there is limited toxicological and epidemiological data
suggestive of a link between paraquat exposure and Parkinson’s
disease, but there remains great controversy and uncertainty over
whether paraquat or other pesticides represents a substantial risk
factor for Parkinson’s disease.
17

J. William Langston, The Etiology of Parkinson’s Disease With
Emphasis on the MPTP Story, 47 NEUROLOGY (6 Suppl 3) 153, 153-60 (1996).
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There is also substantial interest in how chemicals might
modify the immune system. There are three ways by which
chemical interactions with the immune system could be important.
In the first, the chemical may cause direct toxicity to cells of the
immune system, thereby interfering with normal immune
functions. Numerous chemicals, including “dioxin,” have the
ability to interfere with normal immune function, and at sufficient
doses, may disrupt immune function.18 This could lead to enhanced
susceptibility to infection, or perhaps even increased risk of cancer,
since the immune system plays an important role in destroying precancerous and cancerous cells. Establishing whether a particular
chemical has induced immune dysfunction in an individual,
however, would require application of the same basic principles of
toxicology and epidemiology as for any other type of toxic effect,
including “dose-response” and the concept of thresholds.
The second way in which a chemical might interact with the
immune system is through the development of an “allergic”
reaction to the chemical itself. This is illustrated by the common
allergies to penicillin. Some chemicals are capable of triggering the
immune system to develop antibodies against the chemical (or,
more accurately, to a protein in the body that has been modified by
the chemical), and subsequent exposures to that chemical can
induce an allergic response. This is a major concern for many
drugs, as allergic responses can be fatal. Once “sensitization” has
occurred (e.g., the individual has developed antibodies to a specific
chemical), relatively small doses of the chemical may be sufficient
to trigger a response. Thus, people with allergic sensitization to a
specific chemical may respond at a dose much lower than the
“average” person, and the response will be qualitatively different
(e.g., rather than causing liver damage at a high dose seen in most
people, the “allergic” individual may have an asthmatic attack, or
develop skin rashes or GI disturbances, at much lower doses). One
of the most controversial areas in toxicology and environmental
medicine is that related to a number of syndromes such as
18

Michael I. Luster, Michael F. Ackermann, Dori R. Germolec & Gary J.
Rosenthal, Perturbations of the Immune System by Xenobiotics, 81 ENVTL.
HEALTH PERSP. 157, 157-62 (1989).
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“Multiple Chemical Sensitivity” (MCS), Gulf-War Syndrome, Sick
Building Syndrome, Chronic Fatigue Syndrome, etc., for which an
immunological basis may be involved.19 As noted by Kipen and
Fiedler:
Symptoms, and especially those without clear underlying
medical explanations, account for a large percentage of
clinical encounters. Many unexplained symptoms have
been organized by patients and practitioners into
syndromes such as chronic fatigue syndrome, multiple
chemical sensitivity, sick building syndrome, Gulf War
syndrome, and the like. All these syndromes are defined
solely on the basis of symptoms rather than by medical
signs. Some of the above-described conditions overlap
strongly with explained conditions such as asthma. The
relationship of such symptoms and syndromes to
environmental exposure is often sharply debated, as is the
distinction between the various syndromes.20
Litigation in this area often pits toxicologists, epidemiologists,
and/or environmental and occupational medicine specialists against
another group of physicians identified as “clinical ecologists.” As
noted by Goldstein and Henefin:
Clinical ecologists . . . have offered opinions regarding
multiple-chemical hypersensitivity and immune-system
responses to chemical exposures. These physicians
generally have a background in the field of allergy, not
toxicology, and their theoretical approach is derived in part
from classic concepts of allergic responses and
immunology. This theoretical approach has often led
clinical ecologists to find cause-and-effect relationships or

19

See Dalia Racciatti, Jacopo Vecchiet, Annalisa Ceccomancini, Francesco
Ricci & Eligio Pizzigallo, Chronic Fatigue Syndrome Following a Toxic
Exposure, 270 SCI. TOTAL ENV’T 27, 27-31 (2001); see also Roberto Patarca,
Cytokines and Chronic Fatigue Syndrome, 933 ANNALS N.Y. ACAD. SCI. 185,
185-200 (2001).
20
Howard Kipen & Nancy Fiedler, Environmental Factors in Medically
Unexplained Symptoms and Related Syndromes: The Evidence and the
Challenge, 110 (Suppl 4) ENVTL. HEALTH PERSP. 597, 597-99 (2002).
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low-dose effects that are not generally accepted by
toxicologists.21
A third way that chemical exposures might involve the immune
system involves the development of autoimmune diseases such as
lupus, rheumatoid arthritis, and scleroderma. These are important
and disabling diseases, yet our understanding of why the immune
system sometimes goes awry is limited. Autoimmune diseases
arise when the immune system begins to recognize normal tissues
as “abnormal” and mounts an attack to destroy the tissue (similar
to transplant rejection, where the transplanted organ is recognized
as foreign by the immune system). Because the etiology of
autoimmune disease is largely unknown and unpredictable, there
have been many efforts to identify environmental factors that
contribute to the development of autoimmune diseases. Probably
the most extensively studied disease in this regard is lupus
(Systemic Lupus Ereythematosus, SLE). About a half a dozen
drugs have been definitively linked with lupus, with dozens more
implicated.22 However, the list of non-drug “environmental”
chemicals that have been definitively shown to cause lupus (or
other autoimmune diseases) is much shorter. Some inorganic
substances, in particular silica, gold, cadmium, and mercury, have
been shown to induce autoimmunity in animals and humans. There
is suggestive data that exposure to organic solvents, certain
chlorinated hydrocarbons such as vinyl chloride, trichloroethylene,
and hexachlorobenzene, can also induce autoimmunity, although
the scientific evidence (both toxicological and epidemiological) for
this is marginal. It remains an area of scientific interest and
controversy.
D. Environment and Cancer Risk
Claims of cancer, or increased cancer risk, or fear of cancer,

21

Bernard D. Goldstein & Mary Sue Henefin, Reference Guide on
Toxicology, in FED. JUDICIAL CTR., REFERENCE MANUAL ON SCIENTIFIC
EVIDENCE 401, 416 (2d ed. 2000).
22
Evelyn V. Hess, Environmental Chemicals and Autoimmune Disease:
Cause and Effect, 181-182 TOXICOLOGY 65, 65-70 (2002).
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following chemical exposures are often key elements of toxic tort
litigation, and thus I will devote a substantial amount of space to
this particular form of toxic response. While it is clear that some
chemical pollutants (potentially found in air, food, and/or water)
have the ability to cause cancer in either or both experimental
animals and humans, deciding whether a particular chemical
exposure has “more probably than not” been a “substantial
contributing factor”—or whatever the relevant burden of proof
might be—in a particular person’s cancer (or risk of cancer, or fear
of cancer) is a major challenge for scientists, lawyers, judges, and
jurors. To facilitate an understanding of the scientific challenges
that are faced in such litigation, it is perhaps useful to look at the
“big picture” of what scientists know—and don’t know—about the
causes of cancer.
1.

Major Causes (Risk Factors) of Cancer

Over the last fifty or so years, a tremendous amount of
epidemiological data has been collected on the relationship
between a variety of “environmental factors” and the incidence of
cancer. Studies comparing cancer risks in different populations
with various lifestyle, genetic, cultural, dietary, and behavioral
characteristics have led to a reasonable understanding of the major
“risk factors” for cancer. These data are of course based on the
incidence of cancer in large populations, and thus it is difficult to
ascribe “individual” risk to a specific person from these data.
Based on such analyses, it has been stated that 85-90% of all
cancers are “environmentally-related” and thus potentially
preventable. It should again be emphasized, however, that the term
“environmentally-related” in this context refers to everything other
than genetics (including smoking, diet, lifestyle, etc.) and does not
equate directly to “environmental pollution.”
As illustrated in Table 1, approximately 35-40% of all cancer
deaths are attributable to tobacco products.23 While much of this is
23

Richard Doll & Richard Peto, The Causes of Cancer: Quantitative
Estimates of Avoidable Risks of Cancer in the United States Today, 66 J. NAT’L
CANCER INST. 1191, 1191-308 (1981). Most estimates are derived from the
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lung cancer (the leading cause of cancer-related deaths in both men
and women in most developed parts of the world), smoking also
increases risk of oral, bladder, kidney, and several other cancers.
TABLE 1—“BEST ESTIMATES” OF THE MAJOR RISK FACTORS FOR CANCER
Factors
Tobacco
Diet
Cultural and Lifestyle factors
Infectious agents
Genetics
Occupation
Alcohol
Geophysical factors (e.g., radon)
Medicines/medical procedures
Pollution
Industrial Products
Food additives

Best Estimate (%)
35
35
10
10
5
4
3
3
1
2
<1
<1

Range (%)
25 – 40
10 – 70
1 – 13
5 – 20
2 – 10
2–8
2–4
2–4
<1 – 3
<1 – 5
<1 – 2
-5–2

The next most important factor—roughly equal in importance
to smoking—is “diet.” What it is about diet that is so important
remains uncertain. What is clear is that there are many aspects of
the diet that can either increase or decrease cancer risk. For
example, diets high in fruits and vegetables have consistently been
shown to lower the risk of a variety of cancers.24 In some studies,
seminal work of Sir Richard Doll. Id. Recognition of infectious agents as a
substantial contributor to several types of cancer, especially for cervical and
stomach cancer, became evident in the past decade. Id. The American Cancer
Society also discusses the major causes of cancer in their book, entitled:
CANCER: WHAT CAUSES IT, WHAT DOESN’T (2003), available for purchase at
http://www.cancer.org.
24
See John D. Potter, Diet and Cancer: Possible Explanations for the
Higher Risk of Cancer in the Poor, 138 INT’L AGENCY FOR RES. ON CANCER
SCI. PUBLICATIONS 265, 265-83 (1997); Eli Riboli & Teresa Norat,
Epidemiologic Evidence of the Protective Effect of Fruit and Vegetables on
Cancer Risk, 78 (3 Suppl) AM. J. CLINICAL NUTRITION 559S, 559S-569S (2003);
Antonia Trichopoulou, Androniki Naska, Antonis Antoniou, Sharon Friel, Ku
Trygg & Alessandro Turrini, Vegetable and Fruit: The Evidence in Their
Favour and the Public Health Perspective, 73 INT’L J. FOR VITAMIN NUTRITION
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diets high in animal fat have been associated with increased risk of
some common cancers (e.g., breast), but the relationship is not
always seen, and it remains unclear whether the amount and/or
type of fat in the diet are important risk factors. There are also
some chemical contaminants in the diet that may increase cancer
risk, but again for most populations it is not clear how important
natural dietary carcinogens (cancer-causing chemicals) are to
overall cancer risk. In some parts of the world, however, a
common mold contaminant of corn and peanuts—called
“aflatoxin”—is certainly an important contributor to the very high
incidence of liver cancer. It has been shown that aflatoxin is much
more dangerous in populations where hepatitis B viral infections
are common.25
The third most important category of risk factors revolves
around cultural and lifestyle factors, which includes sexual
practices and reproductive factors. Often these cultural factors
interact with other environmental factors, such as viruses. For
example, it is now recognized that almost all cervical cancer is due
to infection with the human papilloma virus (HPV), which is
transmitted through sexual activity. For reasons that are unclear,
cervical tissue in teenage women seems more susceptible to HPV
infection than that in older women. Thus, sexual activity at a
young age is a major risk factor for cervical cancer. While this
disease is relatively easily diagnosed (via Pap smear) and treated if
detected early, large differences in access to medical care and sex
education can make a huge difference in the mortality of this
disease across populations.
Breast cancer is the second leading cause of cancer-related
deaths among women in the United States and many other
developed countries, trailing only smoking-related lung cancer.
The major risk factor for breast cancer appears to be a constellation
of reproductive factors that influence a woman’s “lifetime dose” of
unopposed estrogen. Thus, the age of onset of menstruation, the

RES. 63, 63-69 (2003).
25
Thomas W. Kensler, Gang-Sun Qian, Jiang-Guo Chen & John D.
Groopman, Translational Strategies for Cancer Prevention in Liver, 3 NATURE
REV. CANCER 321, 321-29 (2003).
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age of onset of menopause, the number of children, the age of first
pregnancy, and the extent of breast-feeding, all influence breast
cancer risk. Thus, it is not surprising that breast cancer incidence
and mortality is much lower in countries and cultures where
women have their first children early in life, have multiple
children, breast feed for extended periods, and often have dietary
habits that postpone (or, at least don’t accelerate) the onset of
menstruation, compared to a typical “suburban U.S.” lifestyle.
Recently, there has been much public press coverage of the
discovery of several “breast cancer genes” (BRCA1, BRCA2,
BRCA3).26 Although there is little question that women who carry
variant forms of the genes are at substantially increased risk of
developing breast cancer (especially at a younger age), the overall
contribution of these rather rare genetic causes of breast cancer is
probably substantially less than 10% of all breast cancers. Thus,
the large majority of breast cancers seem not to have major genetic
contributors. But it remains uncertain whether there are important
“environmental susceptibility” genes that might interact with
environmental factor(s) to substantially increase breast cancer risk.
Of the various identifiable “environmental” factors not
associated with diet or lifestyle, infectious agents seem to play a
more important role than was expected only a decade ago. It is
now clear that well over 90% of cervical cancers are due to HPV
infections.27 Many cases of stomach cancer are directly attributable
to a chronic bacterial infection from helicobacter coli.28 Most cases

26

See Peg Brickley, Repairing BRCA1 Science DNA-Repair Researchers
Trying to Separate Sound Science from Allegedly False Data in Retracted
Papers, THE SCIENTIST, June 18, 2003; Jeffrey Krasner, Marketing of CancerGene Test Raises Ethical Medical Concerns: Gene Test Ads Prompt Concern,
BOST. GLOBE, Mar. 26, 2003, at D1; Rick Weiss, 2 Genes Make Cancer Risk
Soar; Women’s Odds Not Tied to Family Health, Study Finds, WASH. POST, Oct.
24, 2003, at A1.
27
See F. Xavier Bosch & Silvia de Sanjose, Human Papillomavirus and
Cervical Cancer—Burden and Assessment of Causality, 31 J. NAT’L CANCER
INST. MONOGRAPHS 3, 3-13 (2003); Steven E. Waggoner, Cervical Cancer, 361
LANCET 2217, 2217-25 (2003).
28
Jon R. Kelley & John M. Duggan, Gastric Cancer Epidemiology and
Risk Factors, 56 J. CLINICAL EPIDEMIOLOGY 1, 1-9 (2003).
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of liver cancer worldwide can be attributable to hepatitis B (and
probably C) viral infections, and alcohol consumption.29 Even the
HIV virus responsible for AIDS is associated with substantially
increased risk for certain types of cancer.30 It is possible, although
still not proven, that a significant fraction of human blood-related
cancers (leukemias and lymphomas) have a viral etiology, as
several leukemia viruses have been identified in animals.
What role do “man-made” chemical pollutants, such as heavy
metals, pesticides, industrial solvents, asbestos, etc., play in overall
cancer risk? As indicated in Table 1, “occupation” is thought to be
responsible for 3-5% of all cancers, although there is reasonable
hope and expectation that this will decline substantially as the long
history of high-level occupational exposures to cancer-causing
substances becomes a relic of the past.31 But the incidence of
asbestos-related lung cancer and mesothelioma, derived from
occupational exposures that occurred predominantly in the ’40s,
’50s, ’60s and early ’70s has not yet peaked, since latency period
(time from first exposure to the development of clinical disease)
may be as long as fifty to sixty years in some individuals. Greatly
improved awareness and early identification of potential cancercausing chemicals, coupled with significant improvements in
workplace controls, monitoring, and worker education (at least in
developed countries) should result in a drastic reduction in the
incidence of occupationally related cancers in the future.
Probably the most uncertain and controversial contributor to
cancer risk is that associated with environmental pollution.32

29

Renuka Bhattacharya & Margaret C. Shuhart, Hepatitis C and Alcohol:
Interactions, Outcomes, and Implications, 36 J. CLINICAL GASTROENTEROLOGY
242, 242-52 (2003); Timothy M. Block, Anand S. Mehta, Claus J. Fimmel &
Robert Jordan, Molecular Viral Oncology of Hepatocellular Carcinoma, 22
ONCOGENEOLOGY 5093, 5093-107 (2003).
30
Eliabeth Y. Chiao & Susan E. Krown, Update on Non-acquired
Immunodeficiency Syndrome-Defining Malignancies, 15 CURRENT OPINIONS
ONCOLOGY 389, 389-97 (2003).
31
See supra note 23 & Tbl. 1.
32
See Julia G. Brody & Riuthann A. Rudel, Environmental Pollutants and
Breast Cancer, 111 ENVTL. HEALTH PERSP. 1007, 1007-19 (2003); Shuanfang
Li, Stephen D. Hursting, Barbara J. Davis, John A. McLachlan & J. Carl Barrett,
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Although it is very difficult to make reasonable “estimates” of the
contribution of environmental pollution to overall cancer incidence
and mortality, most experts place the number at only a few percent,
at most. However, even 1% of 500,000 deaths a year is not an
insignificant number (5000) of potentially preventable deaths, so
efforts to reduce the use and release of chemical carcinogens are
not ill-founded. The challenge comes in balancing the potentially
real, but very low, risks of cancer in a large population against the
societal benefits that come from the industrial and consumer
activities that contribute to the pollution. The basic ways that
chemicals can increase cancer risk (chemical carcinogenesis) and
the process of “carcinogenic risk assessment” for chemical
pollutants are discussed in more detail below.
One example in the area of environmental carcinogenesis that
has been the subject of substantial tort and regulatory litigation is
that of “dioxins.”33 Dioxins represent a group of industrial byproducts produced inadvertently in the chemical manufacture of
trichlorophenol (TCP). TCP was widely used in the synthesis of
the herbicide, 2,4,5 trichlorophenoxy acetic acid (2,4,5-T), a
component of Agent Orange. TCP was also used in the
manufacture of the antibacterial soap ingredient, hexachlorophene,
so many antibacterial soaps were also contaminated with trace
amounts of dioxins. Although there are more than a dozen specific
“dioxin” chemicals, the term is generally used to refer to one
Environmental Exposure, DNA Methylation, and Gene Regulation: Lessons
from Diethylstilbesterol-Induced Cancers, 983 ANNALS N.Y. ACAD. SCI. 161,
161-69 (2003); William G. Thilly, Have Environmental Mutagens Caused
Oncomutations in People?, 34 NAT’L GENETICS 255, 255-59 (2003).
33
See Andrew Blum, Dioxin Cases: Lengths and Results Vary, 10 NAT’L
L.J. 3 (1988); Richard Pliskin, Dioxin Case Ends with a Whimper: Ironbound
Health Rights Advisory Commission v. Diamond Shamrock Chemicals Co., 130
N.J.L.J. 1 (1992); Verdict in One of Nation’s Longest Trials Reached a Year
Ago Saturday (Kemner v. Monsanto), 134 CHIC. DAILY L. BULL. 1 (1988); John
Deakle & Nicholas Varchaver, Muddy Waters; Georgia-Pacific is Mired in
Mississippi, Facing 8,800 Plaintiffs and Billions of Dollars in Potential
Liability, Thanks to Dioxin-Emitting Paper Mill and a Local Plaintiffs Lawyer
Who Won’t Go Away, 15 AM. LAW. 52 (1993); William Boyd, Controlling Toxic
Harms: The Struggle Over Dioxin Contamination in the Pulp and Paper
Industry, 21 STAN. ENVTL. L.J. 345 (2002).
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highly toxic form, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
When tested in experimental animals, TCDD is extremely toxic,
causes cancer and birth defects at extraordinarily low doses, and is
generally considered the most toxic and carcinogenic man-made
chemical ever studied. Dioxins represent an interesting challenge
to the courts for several reasons. First, there are very large species
differences in susceptibility to the toxic—and presumably
carcinogenic—effects of TCDD. For example, the single lethal
dose of dioxin in guinea pigs is approximately 0.1 micrograms per
kg of body weight, whereas the lethal dose in hamsters is more
than 10,000 times greater. Second, although studies in rats and
mice provide consistent evidence that “dioxin” is a potent and
effective carcinogen, human epidemiology studies are less
convincing. Furthermore, dioxin is not appreciably metabolized in
the body, nor does not cause mutations, and the “mechanism” by
which it causes cancer is uncertain. Because it is very soluble in fat
and is not metabolized in the body, it remains in the body for many
years following exposure. Because potentially tens of thousands of
military personnel were exposed to dioxin during the Vietnam
War, and because of the widespread use of certain herbicides
containing small amounts of dioxins in agriculture, forest practices,
utility and highway right of ways, and even residential property, it
has been the subject of extensive toxic tort litigation.34 Although it
is probably one of the most extensively studied chemical
carcinogens, there remains substantial scientific uncertainty as to
the actual levels of cancer risk to humans exposed to trace levels of
dioxins in the environment.
2.

General Mechanisms of Chemical Carcinogenesis

Chemicals that cause an increased incidence of cancer in a
population (experimental animals or humans) following exposure
are referred to as “carcinogens.”35 The process of chemical
carcinogenesis is “multi-stage,” such that several events must
34

See sources cited supra note 33.
CASARETT AND DOULL’S TOXICOLOGY: THE BASIC SCIENCE OF POISONS,
supra note 11, at Ch. 8.
35
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occur before a normal cell is transformed into a malignant (cancer)
cell. Typically, the process of carcinogenesis is divided into four
general stages: (1) initiation, (2) promotion, (3) progression and (4)
metastasis. A chemical carcinogen may increase the incidence of
tumors by acting at any or all of these various stages. One of the
most important ways that a chemical may act as a carcinogen is by
interacting with DNA in somatic cells to cause mutations. (Somatic
cells refer to all cells in the body except sperm and egg cells
(ova)). Mutations in somatic cells may lead to permanent changes
in the DNA that result in critical changes in the way the cell
controls its rate of cell division. Such a permanent alteration in
DNA of a somatic cell is referred to as “initiation,” and represents
the first stage of chemical carcinogenesis. Because initiation
results in a permanent change in the DNA of a cell that is
subsequently passed on to all “daughter” cells following division
of the mutated cells, initiation is generally considered to be an
irreversible process, and initiated cells may accumulate in the body
throughout life.
By definition, all chemicals that are “initiators” are mutagenic,
and thus short-term tests that demonstrate the mutagenic ability of
a chemical make it a suspect carcinogen.36 However, not all
chemicals that test positive in mutagenicity assays are carcinogenic
for a variety of reasons. Nevertheless, a chemical that consistently
tests positive in numerous different short-term mutagenicity assays
is more likely to be carcinogenic than a chemical that routinely
tests negative. However, as with all toxicological responses, the
“dose-response” for mutagenesis is critically important to consider.
Thus, when considering the potential health significance of
exposure to chemical mutagens that may act as carcinogens, it is
important to keep the total or cumulative “dose” in mind, as the
critical issue is whether there is a biologically relevant increase in
the “background” rate of DNA damage from all other sources over
the lifetime of an individual.
Although initiation is an essential first step toward cancer, most
initiated cells do not go on to become cancers because they usually
require additional genetic changes and other external stimuli to
36

Id.
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become true cancer cells. An initiated cell is analogous to a car
whose accelerator is stuck part way on. As long as the brakes
work, the speed and control of the car can be adequately
maintained. However, if a second change occurs, resulting in the
loss of the brakes, then the car can no longer be controlled. It
should be recognized that the vast majority of mutations in a cell
do not have any effect on cell growth and regulation, just as most
mechanical malfunctions in a car do not result in a stuck
accelerator or loss of brakes.
The second step of carcinogenesis, referred to as “promotion,”
occurs when some external stimuli, including exposure to certain
chemicals, increases the rate of cell proliferation of initiated cells
or otherwise enhances the ability of an initiated cell to become
cancerous, but does not directly interact with DNA. A chemical
that increases cancer risk by acting as a promoter of carcinogenesis
is generally considered to be less of a concern because the
promoting stimulus goes away when the exposure stops—e.g.,
promotion is “reversible.” The process of promotion can be viewed
as a relatively early stage in carcinogenesis where an initiated cell
is stimulated to divide repeatedly to give rise to a small colony of
initiated cells (a “preneoplastic” lesion).
The third stage of carcinogenesis, referred to as progression,
represents the long period of time where the small colony of
initiated cells acquires additional mutations that further transform
the cell from a normal cell to a cancer cell. To return to the car
analogy, additional mutations damage the cell’s “brakes,”
“steering,” or other critical functions necessary to properly
maintain control.
The probability of a single cell acquiring all of the necessary
genetic changes to convert it from a normal cell to a cancer cell
depends on a variety of factors, including the dose and duration of
exposure to mutagenic substances. Exposure to man-made
mutagenic chemicals can increase cancer risk. However, it should
be recognized that the vast majority of DNA damage that occurs in
our cells results from normal metabolic processes and exposure to
natural components in the diet or to UV radiation in sunlight. As a
cell “burns” sugars to produce energy it generates reactive byproducts of oxygen. These by-products, called “free radicals” or
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“reactive oxygen species” (ROS) can and do directly damage
DNA. In addition, common chemicals found naturally in the diet
and/or formed during cooking can also damage DNA (e.g., act as
mutagens). Fortunately, the cells of the body have remarkable
processes that can reduce the damage to DNA from ROS and
mutagenic chemicals (both natural and man-made), as well as
repair damaged DNA. Many vitamins and certain chemicals found
naturally in the diet (especially in fruits and vegetables) act as
“antioxidants” and can help protect cells from the DNA damaging
effects of ROS and chemicals (both man-made and natural) that
damage DNA. This is one reason why diet is so important in
lifetime cancer risk. Many studies have demonstrated that diets
high in fruits and vegetables lower the risk of many types of
cancer.37
Because the probability of a single somatic cell acquiring all of
the necessary genetic changes (mutations) to become a cancer cell
is quite small and is a function of the period of time that a cell has
to acquire such mutations, cancers that occur because of exposure
to a carcinogen are both relatively rare in an exposed population
and are usually not seen until many years after the initial period of
exposure. For cancers caused by prolonged or repeated exposure to
a chemical, the time frame from first exposure to when the disease
becomes clinically evident is referred to as the “latency” period. In
general, the latency period is somewhat inversely related to the
extent of exposure (dose). For most human cancers that are related
to chemical carcinogen exposure (e.g., cancers related to cigarette
smoking), the latency period is usually twenty to forty years.
Certain cancers (mesotheliomas) that arise from occupational
exposure to asbestos typically are not seen for thirty or more years
after first exposure.38 The shortest latency period possible appears
to be at least a couple of years following very high levels of
exposure to mutagenic chemicals used to treat cancers, especially
leukemias.39 Because latency seems to be inversely related to dose,
37

See sources cited supra note 24.
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38
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very low levels of exposure to mutagenic chemicals may be of
little practical consequence to an individual because (1) the extent
of DNA damage is very small, relative to the “background” rate
that occurs from all other sources, and (2) the latency period for
developing a cancer is very long and may exceed normal life
expectancy. Although these are very important practical biological
considerations, they are often not considered in quantitative risk
assessment of low dose carcinogen exposures by regulatory
agencies, who usually assume that risk is directly proportional to
dose at low doses (the “linearized dose-response” approach to
cancer risk assessment).
Another factor that affects the occurrence of a cancerous cell is
the rate of cell turnover, or “cell proliferation.”40 Because all cells
have a background incidence of spontaneous mutations, the
likelihood of a cell becoming mutated is related to the rate of cell
replication, analogous to rolling dice. The more often the dice are
rolled the more likely a specific number is to appear. This factor is
especially important in considering the use of high doses of
chemicals in laboratory animal test for cancer-causing potential.
When doses of the test chemical are so high that they cause tissue
damage (and thus stimulate cell division to repair the damage)—
which usually would not occur at low doses—direct extrapolation
of the rate of tumor formation in the animals given high doses to
humans exposed to much lower doses that don’t cause tissue
damage is of questionable scientific value.41 The particular rodent
strains used also often have a high background rate of spontaneous
tumors.42 Thus, any chemical that damages cells and causes
considerable regeneration (i.e., cell proliferation) may increase the
Rowley, Myeloid Leukemia After Hematotoxins, 104 (Suppl 6) ENVTL. HEALTH
PERSP. 1303, 1303-07 (1996).
40
Samuel M. Cohen, Cell Proliferation and Carcinogenesis, 30 DRUG
METABOLISM REV. 339, 339-57 (1998).
41
Samuel M. Cohen, Urinary Bladder Carcinogenesis, 26 TOXICOLOGY
PATHOLOGY 121, 121-27 (1998); Lois S. Gold, Thomas H. Slone & Bruce N.
Ames, What Do Animal Cancer Tests Tell Us About Human Cancer Risk?
Overview of Analysis of the Carcinogenic Potency Database, 30 DRUG
METABOLISM REV. 359, 359-404 (1998).
42
See Gold, supra note 41; see also Zito, supra note 13.
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likelihood of a cancerous cell occurring.
E. Use of Toxicological Data to Assess Chemical Risks in
Populations and Individuals
It is important to recognize that the procedures commonly used
in “risk assessment” for the purposes of establishing public health
guidelines that represent “acceptable” exposure levels for large
populations are often, in this author’s opinion, of marginal
relevance to estimating “causation” in an individual—e.g., whether
a particular chemical caused or contributed to a particular disease
or illness in a given person. Although toxicological data—and the
basic principles of toxicology outlined above—are useful for both
(establishing guidelines for protection of public health and
establishing “causation”), there are substantial differences in
approach. Thus, use of toxicological data for these two distinct
purposes will be discussed separately in the following sections.
F. Use of Toxicological Data to Establish “Acceptable”
Levels of Exposure for Large Populations (Public
Health)
Much of the available dose-response criteria for assessing
chemical toxicity and risks to human health are based on protective
guidelines developed by federal (e.g., EPA, ATSDR) and
sometimes state agencies. The federal government and national
organizations using similar approaches also set occupational health
guidelines and standards for protection of workers. Guidelines for
protection of the general public are usually more stringent than for
workers, who are assumed to be part of a healthier and less
sensitive population. Public health guidelines, however, should not
be interpreted as predicting exact levels at which effects would
occur in a given individual. Because a number of protective, often
“worst-case” assumptions (e.g., exposure to any dose of a
carcinogenic chemical based on animal studies confers a risk of
cancer in humans, high daily exposure for a lifetime) are made in
estimating allowable exposures for large populations, these criteria
and the resulting regulatory levels (e.g., MCLGs, MCLs) generally

EATON.DOC

2/23/2004 7:22 PM

TOXICOLOGY IN LITIGATION

35

overestimate potential toxicity levels for nearly all individuals.
Furthermore, because these guidelines are intended to be protective
of all individuals in a population, including the very young, the
very old, and other potentially “sensitive” individuals, the
theoretical risks from exposure at the guideline level is likely to be
substantially overestimated for the large majority of individuals in
the population. Nevertheless, they can provide useful guidance to
public health agencies that have the responsibility of protecting all
individuals in large populations.
Public Health criteria developed by the EPA for individual
chemicals usually include determination of non-cancer reference
doses and “cancer potency” or “slope factors.” Non-cancer
reference doses represent the dose below which no adverse health
effects are expected, even in sensitive individuals exposed
repeatedly at the defined level for many years. Reference doses are
usually derived from “No Observable Adverse Effect Levels”
(NOAELs) or “Lowest Observable Adverse Effect Levels”
(LOAELs) in the toxicological literature. NOAELs and LOAELs
are usually determined from experimental animal studies, rather
than human exposures. The term “Reference Dose” is frequently
used to refer to a dose of a chemical to humans that could be
consumed on a daily basis for a lifetime with no chance of anyone
exhibiting an adverse response (the specific definition of such
“safe” doses varies from agency to agency and regulation to
regulation). Reference Doses are obtained by dividing the
“NOAEL” dose determined in animal studies by an Uncertainty
Factor. Uncertainty Factors usually range from 100 to 1000,
depending on the amount of uncertainty in, for example,
extrapolating from animals to humans, short-term to long-term
effects, average to sensitive members of the population.43
Generally, the more uncertainty factors required, the more likely it
is that the Reference Dose will be lower than what would actually
be necessary for protection of humans because each uncertainty
factor errs on the side of overprotection. Thus, although health
authorities can confidently expect that exposures below reference
dose levels will not result in adverse effects, the converse is not
43

See sources cited supra notes 13 & 14.
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true. Exposures in a given individual that exceed a reference dose
level do not signify that effects are likely to occur because of the
margin of “safety” built into these Reference Doses which are
intended to provide guidance for protecting even sensitive
members of the population. Thus, such regulatory levels are of
substantial value to public health agencies charged with ensuring
the protection of the public health, but are of limited value in
judging whether a particular exposure was a substantial
contributing factor to a particular individual’s disease or illness.
G. Determining Regulatory Guidelines for Chemical
Carcinogens for Protection of Public Health
For carcinogens, most regulatory agencies have used “default”
assumptions about the dose-response relationship such that it is
assumed that the risk of developing cancer is proportionate to dose
at all doses (e.g., there is no “threshold” dose).44 Thus, to establish
socially acceptable levels of exposure to carcinogens commonly
found in food, air and water, the EPA, FDA, and other regulatory
agencies have established guidelines for conducting risk
assessments.45 Using such procedures, “acceptable,” “tolerable,”
“permissible,” or “safe” levels of exposure to a specific chemical
are often established based on regulatory policy decisions on
allowable risk, or tradeoffs between risk reduction and cost.46 For
contaminants in drinking water, such levels are referred to as
“Maximum Contaminant Levels,” or MCLs. The EPA has a longstanding policy that dictates that the desired level of cancer risk for
a contaminant in drinking water is zero.47 Thus, for carcinogens the
EPA has established MCLGs (Maximum Contaminant Level
Goals) of zero. However, because zero levels are generally not
44

See ENVTL. PROT. AGENCY, EPA 630/P-03/001A, NCEAA-F-0644A,
DRAFT FINAL GUIDELINES FOR CARCINOGEN RISK ASSESSMENT (2003). Earlier
adopted versions also have assumed linearity at low dose. Id.
45
See id.; Zito, supra note 13.
46
See ENVTL. PROT. AGENCY, supra note 44.
47
See U.S. Envtl. Prot. Agency, Setting Standards for Safe Drinking Water,
at http://www.epa.gov/safewater/standard/ setting.html (last modified Aug. 7,
2003).
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achievable by modern technology, the actual drinking water
standards, MCLs, are usually based on other considerations such as
technical feasibility, cost-benefit analysis, and background levels.
However, even if the standard is based primarily on a technology
or cost, MCLs for most such chemicals in drinking water must still
be within an acceptable range of health risk. For cancer risk from
chemicals in drinking water, the EPA has stated this range to be an
excess lifetime risk of cancer over background of one in 1,000,000
to one in 10,000. However, there are some exceptions where
MCLs have been established that yield theoretical excess lifetime
cancer risks much greater than one in 10,000. The recent adoption
of an MCL for arsenic in drinking water of 10 ppb is such an
example.48
Because the lifetime probability of dying from cancer for
someone living in the United States is about 1 in 4 (25%, or 0.25
lifetime probability), a theoretical increase in lifetime cancer risk
(mortality) of 1 in 100,000 would provide a potential increase in
overall lifetime probability of dying from cancer from
approximately 0.25 to approximately 0.25001. Thus, when citizens
are confronted with evidence that their drinking water is
contaminated with a “cancer causing chemical” at levels that
exceed federal regulatory limits, it becomes important to ensure
that the public understands how such standards are derived and the
significance of the potential increase in risk, relative to other
common risks encountered daily.
EPA cancer “slope factors” represent the slope of the doseresponse relationship statistically extrapolated from studies of high
dose exposure and cancer in laboratory animals or human
populations. The EPA default assumption in these slope factors is
that no dose of a carcinogenic chemical is without some risk of
cancer and that one can extrapolate high dose exposures and the
risk of cancer to low doses. The use of a slope factor in this

48

See U.S. Envtl. Prot. Agency, Arsenic in Drinking Water, at
http://www.epa.gov/safewater/arsenic.html (last modified July 14, 2003);
SUBCOMMITTEE TO UPDATE THE 1999 ARSENIC IN DRINKING WATER REPORT,
NAT’L RES. COUNCIL, ARSENIC IN DRINKING WATER: 2001 UPDATE (2001),
available at http://www.nap.edu/catalog/10194.html (last visited Dec. 5, 2003).
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manner ignores the ample evidence that for many carcinogenic
chemicals, practical thresholds may exist for significant cancer risk
because of detoxification mechanisms at low doses (e.g.,
difference in metabolism of the chemicals at high dose versus
lower doses) or because of the mechanisms of action. Therefore,
these slope factors cannot be expected to accurately predict a risk
of cancer, if any, in a given individual at low doses. Although they
may be somewhat useful to make crude estimates of individual
risk, many assumptions go into the determination of the cancer
slope factor, and it is important to consider the relevance of the
particular animal study from which the slope factor was
determined when attempting to use such values in individual risk
calculations.
H. Use of Toxicological Data in Assessment of Individual
Causation
When assessing whether a particular potentially toxic
substance is a substantial contributing factor to an individual’s
disease or illness, the “regulatory approach” is of little value,
although much of the same toxicological and epidemiological data
may be used in evaluating causation. The key scientific criteria
used to establish causation between an alleged chemical exposure
and a particular disease or illness includes the following basic
concepts:
1. The toxic substance in question must have been
demonstrated to cause the type of illness or disease in question.
This addresses the issue of general causation as well as specific
causation, and may be demonstrated either in humans following
known exposures (usually from accidents, occupational exposures,
or intentional exposures), or, in the absence of human data, in
experimental animals intentionally exposed to the agent in
question. Because most chemicals that are widely encountered in
the environment, such as pesticides, metals, and industrial solvents,
are manufactured, workplace exposure to humans may occur.
Occupational health and safety regulations require workplace
monitoring, and thus there is frequently a substantial amount of
toxicologically relevant data from workplace monitoring that can
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be used to assess whether a particular chemical is capable of
causing a particular disease or illness. Indeed, virtually all
synthetic chemicals identified by EPA or International Agency for
Research on Cancer as “known human carcinogens” have been
identified as such through studies of workers exposed to the
chemical in the workplace. Workplace exposures are typically
hundreds to thousands of times greater than incidental
environmental exposures that might occur from contamination of
drinking water, or off-site migration of chemicals via the air.
2. The individual must have been exposed to a sufficient
amount of the substance in question to elicit the health effect in
question. As noted above, the main tenant of toxicology is the
“dose-response” relationship. If criterion (1) above has been
established for a given chemical, then it must be established that
the individual’s dose over a defined period of time was sufficient
to cause the alleged health effect. It is not adequate to simply
establish that “some” exposure occurred. Because most chemically
induced adverse health effects clearly demonstrate “thresholds,”
there must be reasonable evidence that the exposure was of
sufficient magnitude to exceed the threshold before a likelihood of
“causation” can be inferred. For carcinogenic chemicals that act
via mutagenic action, a threshold may not be evident. Thus,
although any level of exposure will theoretically increase the
probability of developing the disease, the risk follows a doseresponse relationship, and the dose must be sufficient to
“significantly” elevate the risk above the background. What
represents a “significant” increase in cancer risk is of course
subjective and influenced by many factors. However, as noted
above, because the process of chemical carcinogenesis is always
associated with a “latency,” and the latency period is generally
inversely related to dose, at very low doses of even “direct acting,”
mutagenic carcinogens, the latency period might exceed life
expectancy, thereby imparting a “practical” threshold.
3. The chronological relationship between exposure and effect
must be biologically plausible. If a disease or illness in an
individual preceded the established period of exposure, then it
cannot be concluded that the chemical caused the disease, although
it may be possible to establish that the chemical aggravated a pre-
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existing condition or disease. For cancer cases, diagnosis of the
cancer in a time frame close to the beginning period of exposure
(i.e., within a few years) argues strongly against a causal
relationship, since, as noted above, chemically-induced cancers
have latency periods that are nearly always in excess of five years,
and are somewhat inversely related to dose.
4. The likelihood that the chemical caused the disease or
illness in an individual should be considered in the context of other
known causes. Although this consideration may not be essential to
establish general causation, it is a critical consideration in the
quantitative assessment of whether the substance was “more likely
than not” a cause or substantial contributing factor to the disease or
illness in a specific person. This is especially important in cancer
causation, because cancer is by its very nature a multi-factorial
disease. As discussed above, chemicals that are mutagenic have the
theoretical potential to increase cancer risk even at very low doses,
although there is a point at which the theoretical risk is trivial,
relative to all other causes, known and unknown. As there are
literally hundreds, if not thousands, of mutagenic naturallyoccurring chemicals present at low levels in our diet and thus also
present theoretical cancer risks, it becomes important to put such
theoretical, “low dose” risks in perspective.49
J. Multiple Exposures/Mixtures
Another area of relevance to human risk assessment for
environmental pollutants is the fact that, unlike experimental
animals, humans may be exposed to multiple different chemicals,
diets, and lifestyle factors that affect the dose-response relationship
for a given chemical. For chemical carcinogens, it is often assumed
that the risks are additive even though they may not act through
similar mechanistic pathways. That is, the risk for each chemical in
a mixture is calculated separately, and the total risk from exposure
to the mixture is simply the sum of the risks for each individual
chemical. While there are examples of non-additive responses
(both “synergistic,” where the response of two chemicals is greater
49

See Kipen & Fiedler, supra note 20.
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than predicted from adding the individual response alone, and
“antagonistic,” where one chemical appears to reduce the risk of
the second), unless there is compelling evidence to the contrary,
additivity of risks for all carcinogens is generally assumed.
However, for carcinogens that act via different modes (e.g.,
genotoxic vs. non-genotoxic carcinogens), additivity is less certain,
and mechanistic data may warrant consideration of non-additive
models for interaction.
EPA risk assessment guidelines also consider non-cancer
effects of chemicals to be additive, particularly if they effect the
same endpoint at lower doses. If the chemicals act by the same
mechanism, then their action could be additive even when
exposure to each is below a dose that would cause effects.
III. FUTURE SCIENTIFIC OPPORTUNITIES AND CHALLENGES IN
TOXIC TORT LITIGATION
The past decade has seen a tremendous advance in DNA-based
technologies that offer exciting challenges and opportunities to the
field of toxicology. The growing area of “toxicogenomics”—the
application of new molecular technologies to understand how
chemicals cause adverse responses in cells, tissues, and
organisms—will eventually play an important role in toxic tort
litigation. Rather than examining the effect of a chemical on one or
a few biochemical pathways, the tools of toxicogenomics provide a
means to examine the global response of a cell to a chemical
stimulus, resulting potentially in a “fingerprint” alteration in
expression of thousands of different genes (transcriptomics),
proteins (proteomics), or cellular metabolites (metabonomics). The
potential exists for such tools to provide convincing proof that a
particular disease was related to a specific chemical exposure,
through unique changes that potentially can be measured years
after the exposure occurred. As noted by Marchant, however,
“many obstacles and uncertainties remain to be resolved before
toxicogenomics data should be used outside the research context
for practical, regulatory or legal applications.”50 Until such time as
50

See Marchant, supra note 6; see also John C. Childs, Toxicogenomics:
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these new scientific approaches to linking specific diseases or
illnesses to specific exposures can be proven reliable, judges,
lawyers, and jurors must rely upon the basic scientific principles of
toxicology and epidemiology to establish causation in toxic torts.

New Chapter in Causation and Exposure in Toxic Tort Litigation, 69 DEF.
COUNCIL J. 441, 441-46 (2002).

